Clinical trial
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
NCT04609566
Study timeline
Study start (actual)2021-01-26Date precision: day
Registry last updated2026-07-06
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Melanomaunresolved
Non-small Cell Lung Cancerunresolved
Interventions
brentuximab vedotinDRUG · verified · RxNorm: brentuximab vedotin
pembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Seagen, a wholly owned subsidiary of Pfizerlead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
RichmondVirginia, United States6LouisvilleKentucky, United States6AuroraColorado, United States5CincinnatiOhio, United States4AustinTexas, United States3OmahaNebraska, United States3TucsonArizona, United States3ChicagoIllinois, United States2Los AngelesCalifornia, United States2DallasTexas, United States2DenverColorado, United States2AlbanyNew York, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04609566 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.